The anti-VEGF monoclonal antibody bevacizu-mab has been evaluated in relapsed DLBCL, resulting in one partial response and eight patients with stable disease as best response, out of 30 evaluable patients; 6-month PFS, the primary study endpoint, was 15% (95% CI 5-26%) [30]. This evidence concerns the gene VEGFA and diffuse large B-cell lymphoma.